• Clinical and Experimental Pediatrics
• /
• 제57권4호
• /
• pp.164-170
• /
• 2014

Influenza causes acute respiratory infections and various complications. Children in the high-risk group have higher complication and hospitalization rates than high-risk elderly individuals. Influenza prevention in children is important, as they can be a source infection spread in their communities. Influenza vaccination is strongly recommended for high-risk children with chronic underlying circulatory and respiratory disease, immature infants, and children receiving long-term immunosuppressant treatment or aspirin. However, vaccination rates in these children are low because of concerns regarding the exacerbation of underlying diseases and vaccine efficacy. To address these concerns, many clinical studies on children with underlying respiratory diseases have been conducted since the 1970s. Most of these reported no differences in immunogenicity or adverse reactions between healthy children and those with underlying respiratory diseases and no adverse effects of the influenza vaccine on the disease course. Further to these studies, the inactivated split-virus influenza vaccine is recommended for children with underlying respiratory disease, in many countries. However, the live-attenuated influenza vaccine (LAIV) is not recommended for children younger than 5 years with asthma or recurrent wheezing. Influenza vaccination is contraindicated in patients with severe allergies to egg, chicken, or feathers, because egg-cultivated influenza vaccines may contain ovalbumin. There has been no recent report of serious adverse events after influenza vaccination in children with egg allergy. However, many experts recommend the trivalent influenza vaccine for patients with severe egg allergy, with close observation for 30 minutes after vaccination. LAIV is still not recommended for patients with asthma or egg allergy.

• Tuberculosis and Respiratory Diseases
• /
• 제72권1호
• /
• pp.1-7
• /
• 2012

Extracorporeal Membrane Oxygenation (ECMO) support to tissue oxygenation has been shown to improve survival in patients with life threatening respiratory distress syndrome or cardiac failure. Extracorporeal life support such as ECMO, including extracorporeal $CO_2$ removal ($ECCO_2R$), is used as temporary support until successful recovery of organs. A recently published multicentre randomized controlled trial, known as the CESAR (conventional ventilation or extracorporeal membrane oxygenation for severe adult respiratory failure) trial, was the first trial to demonstrate the utility of ECMO in acute respiratory distress syndrome (ARDS). During the 2009 influenza A (H1N1) pandemic, there were many reports of patients with severe ARDS related to H1N1 infection treated with ECMO. These reports revealed a high survival rate and effectiveness of ECMO. In this review, we explain the indication of ECMO clinical application, the practical types of ECMO, and complications associated with ECMO. In addition, we explain recent new ECMO technology and management of patients during ECMO support.

• Pediatric Infection and Vaccine
• /
• 제24권2호
• /
• pp.87-94
• /
• 2017

목적: 상기도 감염인 소아에게 항생제를 처방하는 것은 아직도 많은 진료실에서 이루어지고 있다. 이 연구는 역전사 중합효소연쇄반응 검사로 호흡기 바이러스가 확인된 이후에도 항생제를 사용한 소아 환자들의 임상적 특징을 조사하고자 하였다. 방법: 2013년 1월부터 2014년 11월에 고신대학교 복음병원 소아청소년과에 상기도 감염으로 입원한 환자 중 역전사 중합효소연쇄반응을 시행한 환자들을 대상으로 후향적 의무기록 분석을 통해 평가하였다. 결과: 상기도 감염으로 진단받은 393명 중 전체 환자 연령의 중앙값은 23개월이었다. 입원 당시 항생제를 처방받은 환자(79명, 20.1%)와 항생제를 처방받지 않은 환자들의 임상적 요인을 비교할 때, 중이염 또는 부비동염의 동반, 높은 고감도 C-반응단백질의 수치가 항생제 처방과 의미 있게 관련 있었다(P<0.001). 입원하여 항생제를 사용하던 중 역전사 중합효소연쇄반응 방법으로 호흡기 바이러스가 확인되었지만, 항생제를 계속 사용한 환자는 44명 중 28명(63.6%)이었다. 항생제를 계속 사용한 환자는 항생제를 중단한 환자와 비교할 때 중이염 동반 비율이 유의하게 높았다(75% vs. 25%, P=0.002). 결론: 본 연구에서 상기도 감염의 원인이 바이러스임을 확인된 소아 환자에게서도 항생제를 지속한 주된 이유는 중이염이 동반되었기 때문이었다. 중이염을 정확하게 진단하고 그 중 항생제가 꼭 필요한 경우를 가려낸다면 소아 상기도 감염에서 불필요한 항생제 사용을 줄이는 데 도움이 될 것으로 생각된다.

• Tuberculosis and Respiratory Diseases
• /
• 제78권4호
• /
• pp.366-370
• /
• 2015

Although influenza A (H1N1) virus leads to self-limiting illness, co-infection with bacteria may result in cases of severe respiratory failure due to inflammation and necrosis of intra-airway, as pseudomembranous tracheobronchitis. Pseudomembranous tracheobronchitis is usually developed in immunocompromised patients, but it can also occur in immunocompetent patients on a very rare basis. We report a case of pseudomembranous tracheobronchitis complicated by co-infection of inflenaza A and Staphylococcus aureus, causing acute respiratory failure in immunocompetent patients.

• Pediatric Infection and Vaccine
• /
• 제14권2호
• /
• pp.179-187
• /
• 2007

목 적 : 바이러스는 급성 호흡기 감염증의 가장 흔한 원인이며 특히 소아에서 잘 이환되고, 상기도 감염뿐 아니라 하기도 감염을 일으켜 모세기관지염, 폐렴, 크룹, 기관기관지염 등을 일으킨다. 이러한 원인이 되는 바이러스들의 유행을 조사하기 위해 본 연구를 시작하였다. 방 법 : 2004년 1월부터 2006년 12월까지 만 3년 동안 부산지역 26개소 병원, 의원, 보건소에 급성 호흡기 증상으로 내원하였던 0-18세의 환자 중 기침, 콧물, 발열, 인후통을 보였던 환자들을 대상으로 하였고, 8,974명에서 비인두 면봉법으로 검체를 채취하였으며 이 중 281례(3.0%)에서 바이러스가 분리되었다. 결 과 : 1) A형 인플루엔자 바이러스가 131례(46.6%)로 가장 많았으며 2004년 봄에 특히 많이 검출되었다. 그 이외에도 RS 바이러스가 40례(14.2%), B형 인플루엔자 바이러스가 37례(13.2%), 아데노바이러스가 23례(8.2%), 장내바이러스가 37례(13.2%) [콕사키바이러스 20례(7.1%), 비정형 장내바이러스 9례(3.2%), 폴리오바이러스 4례(1.4%), 에코바이러스 4례(1.4%)], 파라인플루엔자 바이러스가 2례(0.7%), 그리고 코로나바이러스, 보카바이러스가 각각 1례(0.4%) 검출되었다. 2) 대상이 되었던 8,974명의 환아에서 281례의 양성결과 중 남아에서 163례(56%), 여아에서 123례(44%)로 남녀 성비는 약 1.3:1로 남자에서 약간 더 많았다. 연령별로는 0-1세에서 195례(69%), 2-10세에서 78례(28%), 11-18세에서 8례(3%)가 분리되었다. 3) RS 바이러스는 매년 분리되었으나 주로 10월에서 2월에 많았고, A형 인플루엔자 바이러스는 매년 12월에서 4월에 주로 분리되었으며. B형 인플루엔자 바이러스는 2-4월에 분리되었다. 아데노바이러스는 연중 고루 발생하였으며, 장내바이러스(비정형 장내바이러스, 콕사키바이러스, 에코바이러스 등)는 5-9월 사이 특히 7-8월에 집중적으로 발생하였다. 파라인플루엔자 바이러스는 주로 5-7월에 발생하였다. 결 론 : 저자들은 부산지역에서 최근 3년간 유행한 급성 호흡기 질환의 원인 바이러스를 분석하여 역학적 특징을 규명하였으며, 향후 이러한 바이러스에 의한 급성 호흡기 질환을 예방하고 치료하는데 도움이 될 수 있도록 발생 시기와 유행 양상에 대한 더 많은 보고와 연속적인 연구가 필요할 것이다.

• Journal of Microbiology and Biotechnology
• /
• 제30권3호
• /
• pp.313-324
• /
• 2020

Coronavirus disease 2019 (COVID-19), which causes serious respiratory illness such as pneumonia and lung failure, was first reported in Wuhan, the capital of Hubei, China. The etiological agent of COVID-19 has been confirmed as a novel coronavirus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is most likely originated from zoonotic coronaviruses, like SARS-CoV, which emerged in 2002. Within a few months of the first report, SARS-CoV-2 had spread across China and worldwide, reaching a pandemic level. As COVID-19 has triggered enormous human casualties and serious economic loss posing global threat, an understanding of the ongoing situation and the development of strategies to contain the virus's spread are urgently needed. Currently, various diagnostic kits to test for COVID-19 are available and several repurposing therapeutics for COVID-19 have shown to be clinically effective. In addition, global institutions and companies have begun to develop vaccines for the prevention of COVID-19. Here, we review the current status of epidemiology, diagnosis, treatment, and vaccine development for COVID-19.

• Tuberculosis and Respiratory Diseases
• /
• 제80권4호
• /
• pp.325-335
• /
• 2017

Chronic obstructive pulmonary disease (COPD) is associated with abnormal inflammatory response and airflow limitation. Acute exacerbation involves increased inflammatory burden leading to worsening respiratory symptoms, including dyspnea and sputum production. Some COPD patients have frequent exacerbations (two or more exacerbations per year). A substantial proportion of COPD patients may remain stable without exacerbation. Bacterial and viral infections are the most common causative factors that breach airway stability and lead to exacerbation. The increasing prevalence of exacerbation is associated with deteriorating lung function, hospitalization, and risk of death. In this review, we summarize the mechanisms of airway inflammation in COPD and discuss how bacterial or viral infection, temperature, air pollution, eosinophilic inflammation, and concomitant chronic diseases increase airway inflammation and the risk of exacerbation.

• Tuberculosis and Respiratory Diseases
• /
• 제85권4호
• /
• pp.283-288
• /
• 2022

Asthma is a chronic inflammatory disease of the airways characterized by varying and recurrent symptoms, reversible airway obstruction, and bronchospasm. In this paper, clinical important studies on asthma published between March 2021 and February 2022 were reviewed. A study on the relationship between asthma and chronic rhinosinusitis, bronchiectasis, and hormone replacement therapy was published. A journal on the usefulness of fractional exhaled nitric oxide for the prediction of severe acute exacerbation was also introduced. Studies on the effect of inhaler, one of the most important treatments for asthma, were published. Studies on the control of severe asthma continued. Phase 2 and 3 studies of new biologics were also published. As the coronavirus disease 2019 (COVID-19) pandemic has been prolonged, many studies have explored the prevalence and mortality of COVID-19 infection in asthma patients.

• Tuberculosis and Respiratory Diseases
• /
• 제69권2호
• /
• pp.75-80
• /
• 2010

The year of 2009~2010 brought a number of concepts and new ideas were evaluated with promising results. However, some studies that challenged many beliefs. In acute respiratory distress syndrome (ARDS), recent clinical studies took into consideration of pathophysiologic changes of respiratory system compliance. Meta-analysis of positive end-expiratory pressure trials showed survival benefit of high positive end-expiratory pressure in ARDS. Until now, prone positioning did not show survival benefit in patients with ARDS. Extracorporeal membrane oxygenation (ECMO) based management improved survival in patients with severe ARDS. ECMO can be a management option in severe ARDS. Sedation is a standard practice in critically ill patients needing mechanical ventilation. However, Danish group reported less sedation of critically ill patients receiving mechanical ventilation was associated with an increase in days without ventilation. Although this single center study has some limitations, the overall results are promising. Use of maximal sterile barrier precautions (mask, sterile gown, sterile gloves, and large sterile drapes) with chlorhexidine-impregnated dressing reduced central venous catheter related infection. Selective oropharyngeal decontamination (application of topical antibiotics in the oropharynx) reduced the mortality rate of an intensive care unit (ICU) population. Normoglycemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation (NICE-SUGAR) trial reported intensive glucose control increased mortality among adults in the ICU. Some of the results of above papers are promising. However, some ideas may need for more frequent individual assessment and increase the workload of ICU staffs. Before implementation of new practice in ICU, we should take into consideration of individual hospital situation including human and material resources.

• Animal Bioscience
• /
• 제36권1호
• /
• pp.43-52
• /
• 2023

Objective: This study aimed to examine the influence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on pregnancy in cytokeratin-18 (K18)-hACE2 transgenic mice. Methods: To determine the expression of hACE2 mRNA in the female reproductive tract of K18-hACE2 mice, real-time polymerase chain reaction (RT-PCR) was performed using the ovary, oviduct, uterus, umbilical cord, and placenta. SARS-CoV-2 was inoculated intranasally (30 μL/mouse, 1×10⁴ TCID₅₀/mL) to plug-checked K18-hACE2 homozygous female mice at the pre-and post-implantation stages at 2.5 days post-coitum (dpc) and 15.5 dpc, respectively. The number of implantation sites was checked at 7.5 dpc, and the number of normally born pups was investigated at 20.5 dpc. Pregnancy outcomes, including implantation and childbirth, were confirmed by comparison with the non-infected group. Tissues of infected mice were collected at 7.5 dpc and 19.5 dpc to confirm the SARS-CoV-2 infection. The infection was identified by performing RT-PCR on the infected tissues and comparing them to the non-infected tissues. Results: hACE2 mRNA expression was confirmed in the female reproductive tract of the K18-hACE2 mice. Compared to the non-infected group, no significant difference in the number of implantation sites or normally born pups was found in the infected group. SARS-CoV-2 infection was detected in the lungs but not in the female reproductive system of infected K18-hACE2 mice. Conclusion: In K18-hACE2 mice, intranasal infection with SARS-CoV-2 did not induce implantation failure, preterm labor, or miscarriage. Although the viral infection was not detected in the uterus, placenta, or fetus, the infection of the lungs could induce problems in the reproductive system. However, lung infections were not related to pregnancy outcomes.